Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer.
- Phase III VISION study with 177Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer1
- VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021
- Novartis is committed to reimagining prostate cancer through targeted radioligand therapy with 177Lu-PSMA-617
- More than 15 dedicated early to late development and research programs underway to identify the next wave of radioligand therapies for cancer